Drugs / 68Ga-DFC413
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07630961 | Jun 2026 → Jan 2028 expected | breast lobular carcinoma, colorectal cancer, hormone receptor-positive breast cancer, non-small cell lung carcinoma +3 | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-DFC413 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07630961 ↗ |
| Modality | Diagnostic / imaging agent | “Radioimaging agent” NCT07630961 ↗ |